pneumococcus conjugate vaccine 7 valent to reduce carriage
Biologicalplain polisacaride vaccine 23 valent to reduce carriage
NCT Number: NCT00580684
To compare the ability of Prevnar® to Pneumo® 23 in reducing and preventing nasopharyngeal carriage of vaccine-type pneumococci one year after respective immunization. To evaluate the rate of penicillin-resistant pneumococci in nasopharyngeal carriage.
Looking for future studies?
Notify Me2 year–9 year
All sexes
Interventional
Phase 4
This study will require 6 months to be completed (3 months for nasopharyngeal samples collection; 3 months dor analysis). Each child will participate for a 1 day period.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
plain polisacaride vaccine 23 valent to reduce carriage
Time frame: 12 months
Time frame: 12 months
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Long-Term Efficacy of Pneumococcal Conjugate 7-Valent Vaccine Versus Plain Polisaccharide Pneumococcus Vacine in Reducing Pneumococcal Nasopharyngeal Carriage of Children.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00474539
Vaccines, Pneumococcal
A Coruña, Spain
View Trial DetailsNCT00366899
Vaccines, Pneumococcal
Taranto, Apulia, Italy
View Trial DetailsNCT00294294
Body Temperature Changes, Drug Therapy, Combination
View Trial DetailsNCT00373958
Vaccines, Pneumococcal
Fayetteville, Arkansas, United States
View Trial Details